
    
      Patients with platinum-resistant invasive epithelial ovarian, fallopian tube or peritoneal
      cancer will be randomized 1:2 to either hormonal treatment with Tamoxifen 40 mg daily or
      chemotherapy of investigator's choice (weekly paclitaxel given as an 1 hour infusion of
      paclitaxel 80 mg/m2 or pegylated liposomal doxorubicin 40 mg/m2 given every 4 weeks).
    
  